135 related articles for article (PubMed ID: 20351350)
1. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.
Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Mechtersheimer G; Schmitt T; Lehner B; Haberkorn U; Stroebel P; Kasper B
J Nucl Med; 2010 Apr; 51(4):551-8. PubMed ID: 20351350
[TBL] [Abstract][Full Text] [Related]
2. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.
Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Schmitt T; Haberkorn U; Kasper B
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1481-9. PubMed ID: 20336454
[TBL] [Abstract][Full Text] [Related]
3. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET.
Dimitrakopoulou-Strauss A; Hoffmann M; Bergner R; Uppenkamp M; Haberkorn U; Strauss LG
Clin Nucl Med; 2009 Sep; 34(9):576-84. PubMed ID: 19692817
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography.
Kasper B; Dietrich S; Dimitrakopoulou-Strauss A; Strauss LG; Haberkorn U; Ho AD; Egerer G
Onkologie; 2008 Mar; 31(3):107-12. PubMed ID: 18322413
[TBL] [Abstract][Full Text] [Related]
5. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis.
Okazumi S; Dimitrakopoulou-Strauss A; Schwarzbach MH; Strauss LG
Hell J Nucl Med; 2009; 12(3):223-8. PubMed ID: 19936332
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
Benz MR; Czernin J; Allen-Auerbach MS; Tap WD; Dry SM; Elashoff D; Chow K; Evilevitch V; Eckardt JJ; Phelps ME; Weber WA; Eilber FC
Clin Cancer Res; 2009 Apr; 15(8):2856-63. PubMed ID: 19351756
[TBL] [Abstract][Full Text] [Related]
7. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C
J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900
[TBL] [Abstract][Full Text] [Related]
8. [Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma].
Kasper B; Schmitt T; Wuchter P; Ho AD; Egerer G
Dtsch Med Wochenschr; 2009 Sep; 134(39):1922-6. PubMed ID: 19760551
[TBL] [Abstract][Full Text] [Related]
9. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of
Chodyla M; Demircioglu A; Schaarschmidt BM; Bertram S; Bruckmann NM; Haferkamp J; Li Y; Bauer S; Podleska L; Rischpler C; Forsting M; Herrmann K; Umutlu L; Grueneisen J
J Nucl Med; 2021 Mar; 62(3):348-353. PubMed ID: 32737246
[TBL] [Abstract][Full Text] [Related]
11. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
[TBL] [Abstract][Full Text] [Related]
12. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology.
Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S
Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176
[TBL] [Abstract][Full Text] [Related]
13. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
Dimitrakopoulou-Strauss A; Strauss LG; Burger C; Rühl A; Irngartinger G; Stremmel W; Rudi J
J Nucl Med; 2004 Sep; 45(9):1480-7. PubMed ID: 15347714
[TBL] [Abstract][Full Text] [Related]
14. PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
Dimitrakopoulou-Strauss A; Strauss LG; Rudi J
Q J Nucl Med; 2003 Mar; 47(1):8-13. PubMed ID: 12714949
[TBL] [Abstract][Full Text] [Related]
15. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas.
Wendtner CM; Abdel-Rahman S; Krych M; Baumert J; Lindner LH; Baur A; Hiddemann W; Issels RD
J Clin Oncol; 2002 Jul; 20(14):3156-64. PubMed ID: 12118030
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.
Herrmann K; Benz MR; Czernin J; Allen-Auerbach MS; Tap WD; Dry SM; Schuster T; Eckardt JJ; Phelps ME; Weber WA; Eilber FC
Clin Cancer Res; 2012 Apr; 18(7):2024-31. PubMed ID: 22338012
[TBL] [Abstract][Full Text] [Related]
17. Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study.
Issels RD; Bosse D; Abdel-Rahman S; Starck M; Panzer M; Jauch KW; Stiegler H; Berger H; Sauer H; Peter K
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S233-7. PubMed ID: 8453705
[TBL] [Abstract][Full Text] [Related]
18. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
Evilevitch V; Weber WA; Tap WD; Allen-Auerbach M; Chow K; Nelson SD; Eilber FR; Eckardt JJ; Elashoff RM; Phelps ME; Czernin J; Eilber FC
Clin Cancer Res; 2008 Feb; 14(3):715-20. PubMed ID: 18245531
[TBL] [Abstract][Full Text] [Related]
19. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.
Avril N; Sassen S; Schmalfeldt B; Naehrig J; Rutke S; Weber WA; Werner M; Graeff H; Schwaiger M; Kuhn W
J Clin Oncol; 2005 Oct; 23(30):7445-53. PubMed ID: 16157939
[TBL] [Abstract][Full Text] [Related]
20. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax.
Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS
Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
